Yale University researchers have developed a new airborne method for delivering mRNA right to your lungs. The team has also used the method to vaccinate mice intranasally,1 opening the door for human testing in the near future.
While scientists are hailing the creation as an easy way to vaccinate the masses, critics wonder if the development of an airborne vaccine could be used for nefarious purposes, including covert bioenhancements,2 which have already been recommended in academic literature.3
Yale Team Develops Airborne mRNA, Delivers It to Lungs
In a study on mice, Yale scientists created polymer nanoparticles to encapsulate mRNA, making it inhalable so it can reach the lungs. Courtney Malo, editor with Science Translational Medicine, which published the study, explained:4
“The ability to efficiently deliver mRNA to the lung would have applications for vaccine development, gene therapy, and more. Here, Suberi et al. showed that such mRNA delivery can be accomplished by encapsulating mRNAs of interest within optimized poly(amine-co-ester) polyplexes [nanoparticles].
Polyplex-delivered mRNAs were efficiently translated into protein in the lungs of mice with limited evidence of toxicity. This platform was successfully applied as an intranasal SARS-CoV-2 vaccine, eliciting robust immune responses that conferred protection against subsequent viral challenge. These results highlight the potential of this delivery system for vaccine applications and beyond.”
The team, led by cellular and molecular physiologist Mark Saltzman, explained that the inhalable mRNA vaccine successfully protected against SARS-CoV-2, which “opens the door to delivering other messenger RNA (mRNA) therapeutics for gene replacement therapy and other treatments in the lungs.”5
For the study, mice received two intranasal doses of nanoparticles carrying mRNA COVID-19 vaccines, which proved to be effective in the animals. In the past, lung-targeted mRNA therapies had trouble making it into the cells necessary to express the encoded protein, known as poor transfection efficiency.6
“The Saltzman group got around this hurdle in part by using a nanoparticle made from poly(amine-co-ester) polyplexes, or PACE, a biocompatible and highly customizable polymer,” a Yale University news release explained.7 In a previous study, Saltzman had tried a “prime and spike” system to deliver COVID-19 shots, which involved injecting mRNA shots into a muscle, then spraying spike proteins into the nose.8
It turned out the injection portion may be unnecessary, and Saltzman has high hopes for the airborne delivery method, beyond vaccines:9
All Global Research articles can be read in 51 languages by activating the Translate Website button below the author’s name. To receive Global Research’s Daily Newsletter (selected articles), click here. Click the share button above to email/forward this article to your friends and colleagues...
www.globalresearch.ca
www.biznews.com
www.rte.ie
www.independent.ie
